Abstract
As physicians, we are notoriously ignorant when it comes to money matters, both in personal and professional matters. As advocates for our patients, our decisions regarding interventions or therapies are more often based on issues of availability, safety, and efficacy than on cost. It is only in our roles as members of the hospital epidemiology team or pharmacy and therapeutics committee that issues of costs play a pivotal role in decision making, especially regarding the use of therapeutics or technical devices that may prevent health care-related infections, such as bloodstream infections. The clear and ob-
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: Clinical Infectious Diseases
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
